India, 12 December 2025: Danish drugmaker Novo Nordisk pra taikhan laa blockbuster diabetes therapy Ozempic launch krui shey India te, ekta strategic expansion mark kuri shey duniya laka sopse populous aro hotai din grow hoi thaka metabolic-bimar market te. Company khan market-specific pricing introduced kuri shey once-weekly injectable karne, starting toh 0.25mg dose te set kuri shey Rs 2,200 te. Step-up 0.5g does toh priced kuri shey Rs 2,542 per week, tadeh 1mg maintenance dose toh Rs 2,793 hubo per week.
Vikrant Shrotriya, managing director Novo Nordisk India, taila hisap te, company toh koshis kuri shey address kuribo leh drug laka affordability issue opor te etu tailored price points through. Ozempic te semaglutide ase- ekta same active ingredient Wegovy te, kun toh India te gusi shey June te weight-loss therapy hoina.
Add Comment